Form 4: NeuroOne Medical Technologies Executive Steve Mertens Reports Stock Disposal
SEC Form 4 Filing
Steve Mertens, Chief Technology Officer of NeuroOne Medical Technologies, reported the disposal of 252 shares of common stock on January 31, 2025, to cover tax obligations.
Summary
- On January 31, 2025, Steve Mertens, the Chief Technology Officer of NeuroOne Medical Technologies Corp, disposed of 252 shares of common stock.
- The transaction was executed at a price of $1.15 per share.
- This disposal was likely to cover tax obligations, as indicated by transaction code 'F'.
- Following the transaction, Mertens directly owns 171,423 shares of NeuroOne Medical Technologies Corp.
- The report was filed on February 4, 2025.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of a routine transaction. It doesn't indicate any positive or negative sentiment about the company's prospects.
Industry Context
This is a routine disclosure of an insider transaction. It's common for executives to sell shares to cover tax obligations related to stock-based compensation.
Stakeholder Impact
- The disposal of shares by an executive could be perceived negatively by some shareholders, but it's a small transaction and likely related to tax obligations.
Key Dates
| Date | Description |
|---|---|
| 01/31/2025 | Date of stock disposal transaction |
| 02/04/2025 | Date of Form 4 filing |
Keywords
NeuroOne Medical Technologies, NMTC, Steve Mertens, Form 4, Stock Disposal, Insider Trading, Chief Technology Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.